Trial Profile

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Infection in Immuno-Suppressed Cancer Patients

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilgavimab/tixagevimab (Primary) ; Cilgavimab/tixagevimab (Primary)
Indications COVID 2019 infections
Focus Pharmacokinetics

Most Recent Events

06 Sep 2023 Status changed from recruiting to discontinued because FDA withdrew EUA for AZD7442.
06 Sep 2022 According to an IsoPlexis media release, the company to partner with with MediMergent, LLC, and The Center for Cancer and Blood Disorders (CCBD), an American Oncology Partners of Maryland practice, to conduct this study.
06 Jul 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com